CD37 expression in follicular lymphoma
CD37 expression in follicular lymphoma
复制标题
DOI：
10.1007/s00277-022-04785-z
复制
发表时间：
2022-02
影响因子：
3.5
通讯作者：
Takuro Yoshimura;H. Miyoshi;J. Shimono;Kazutaka Nakashima;M. Takeuchi;E. Yanagida;K. Yamada;Yasumasa Shimasaki;M. Moritsubo;T. Furuta;K. Kohno;K. Ohshima
中科院分区：
文献类型：
--
作者：
Takuro Yoshimura;H. Miyoshi;J. Shimono;Kazutaka Nakashima;M. Takeuchi;E. Yanagida;K. Yamada;Yasumasa Shimasaki;M. Moritsubo;T. Furuta;K. Kohno;K. Ohshima
CD 37是在多种B细胞淋巴瘤中表达的四跨膜蛋白，其介导肿瘤存活信号传导。滤泡性淋巴瘤（FL）是由生发中心B细胞组成的典型B细胞肿瘤。近年来，CD 37作为B细胞淋巴瘤的治疗靶点受到关注。本研究的目的是描述FL患者中CD 37的表达，以确定与各种预后因素相关的风险因素。我们回顾性分析了167例FL的免疫组化表达及其与临床病理特征的统计学关系。免疫组化显示，CD 37在肿瘤细胞的胞浆和/或胞膜上均有表达，主要分布于不同程度的瘤性滤泡中。100例（100/167，60.0%）被归类为CD 37阳性，67例为CD 37阴性。在滤泡性淋巴瘤国际预后指数（FLIPI）高的病例中，CD 37阴性病例的总生存率低于CD 37阳性病例（P= 0.047），尽管在其他临床病理因素（包括组织学分级、BCL 2-IGH易位和免疫组化表型）中未观察到显著差异。因此，CD 37蛋白可能在肿瘤进展中发挥作用，并可能作为治疗靶点。然而，需要进一步的研究来探讨其意义。
CD37 is a tetraspanin protein expressed in various B-cell lymphomas that mediates tumor survival signaling. Follicular lymphoma (FL) is a representative B-cell neoplasm composed of germinal center B cells. In recent years, CD37 has been focused on as a therapeutic target for B-cell lymphoma. The purpose of this study was to characterize CD37 expression in FL patients to identify risk factors associated with various prognostic factors. We retrospectively reviewed 167 cases of FL and evaluated the immunohistochemical expression of CD37 and its statistical association with clinicopathological features. Immunohistochemically, CD37 was observed in the cytoplasm and/or membrane of neoplastic cells, mainly in neoplastic follicles to various extents. One hundred cases (100/167, 60.0%) were categorized as CD37-positive, and 67 cases were CD37-negative. In cases with high Follicular Lymphoma International Prognostic Index (FLIPI), CD37-negative cases had a poor overall survival compared with CD37-positive cases (P= 0.047), although no significant differences were observed in other clinicopathologic factors, including histological grade, BCL2-IGH translocation, and immunohistochemical phenotype. Therefore, CD37 protein may play a role in tumor progression and may serve as a therapeutic target. However, further studies are needed to explore its significance.